Chen X, Cao J, Chen B Y
Department of Respiratory Medicine, General Hospital, Tianjin Medical University, Tianjin 300052, China (Chen Xin is working in the Department of Respiratory of Tianjin Fourth Center Hospital).
Zhonghua Yi Xue Za Zhi. 2016 Jul 12;96(26):2086-90. doi: 10.3760/cma.j.issn.0376-2491.2016.26.010.
To observe the interleukin-17 (IL-17) expression in lung tussiue of patients with stable chronic obstructive pulmonary disease (COPD) and investigate the clinical significance.
A total of 50 patients receiving lung resections in General Hospital, Tianjin Medical University for lung cancer from October 2010 to October 2011 were included and divided into non-smoking COPD group (NS group), smoking non-COPD group (S group), smoking COPD group (COPD group) according to smoking status and 2013 COPD diagnosis standard. The expression of IL-17 was detected by immumohistochemical staining. The volume of IL-17 in the airway and lung parenchyma was calculated by immumohistochemical staining scores which was product of dyeing cells positive rate and intensity. Pearson correlation analysis was used to analyze the relationships between expression of IL-17 in the airway and lung parenchyma and forced expiratory volume in 1 second/predicted value (FEV1%pred), carbon monoxide diffusion amount accounting for the percentage of the expected value (DLCO%pred), COPD assessment test (CAT) score, body mass index (BMI).
The expressions of IL-17 in airway and lung parenchyma in S group (5.6±3.1, 6.4±2.5) were higher than those in NS group (1.6±1.4, 1.4±1.2) (both P<0.05), while expressions in COPD group (7.3±2.5, 7.8±2.1) were further higher than S group (both P<0.05). In the S group and COPD group, the expressions of IL-17 in the airway and lung parenchyma were positively correlated with smoking (r=0.453, P=0.007 and r=0.573, P<0.001); In the COPD group, the expressions of IL-17 in the airway and lung parenchyma were negatively correlated with FEV1%pred (r=-0.729, P=0.001 and r=-0.489, P=0.039), negatively related with DLCO%pred (r=-0.493, P=0.038 and r=-0.520, P=0.027), positively correlated with COPD CAT score (r=0.730, P=0.001 and r=0.644, P=0.004) and negatively related with BMI (r=-0.653, P=0.003 and r=-0.485, P=0.041).
Smoking increases inflammation of lung tissue, increases IL-17 expression in airway and lung parenchyma; the expression of IL-17 is closely related to the severity of disease, the quality of life and prognosis in COPD patients.
观察稳定期慢性阻塞性肺疾病(COPD)患者肺组织中白细胞介素-17(IL-17)的表达情况并探讨其临床意义。
选取2010年10月至2011年10月在天津医科大学总医院因肺癌接受肺切除术的50例患者,根据吸烟状况及2013年COPD诊断标准分为非吸烟COPD组(NS组)、吸烟非COPD组(S组)、吸烟COPD组(COPD组)。采用免疫组织化学染色法检测IL-17的表达。通过免疫组织化学染色评分计算气道和肺实质中IL-17的量,该评分是染色阳性细胞率与强度的乘积。采用Pearson相关分析气道和肺实质中IL-17表达与第1秒用力呼气容积/预计值(FEV1%pred)、一氧化碳弥散量占预计值百分比(DLCO%pred)、COPD评估测试(CAT)评分、体重指数(BMI)之间的关系。
S组气道和肺实质中IL-17的表达(5.6±3.1,6.4±2.5)高于NS组(1.6±1.4,1.4±1.2)(均P<0.05),而COPD组(7.3±2.5,7.8±2.1)的表达进一步高于S组(均P<0.05)。在S组和COPD组中,气道和肺实质中IL-17的表达与吸烟呈正相关(r=0.453,P=0.007;r=0.573,P<0.001);在COPD组中,气道和肺实质中IL-17的表达与FEV1%pred呈负相关(r=-0.729,P=0.001;r=-0.489,P=0.039),与DLCO%pred呈负相关(r=-0.493,P=0.038;r=-0.520,P=0.027),与COPD CAT评分呈正相关(r=0.730,P=0.001;r=0.644,P=0.004),与BMI呈负相关(r=-0.653,P=